دورية أكاديمية
أعرض في EDS

Functionalized chitosan nanoparticles for cutaneous delivery of a skin whitening agent: an approach to clinically augment the therapeutic efficacy for melasma treatment.

التفاصيل البيبلوغرافية
العنوان: Functionalized chitosan nanoparticles for cutaneous delivery of a skin whitening agent: an approach to clinically augment the therapeutic efficacy for melasma treatment.
المؤلفون: Hatem S; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, New Cairo, Egypt., Elkheshen SA; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt., Kamel AO; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt., Nasr M; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt., Moftah NH; Department of Dermatology, STD's and Andrology, Faculty of Medicine, Minia University, Al-Minya, Egypt., Ragai MH; Department of Dermatology, STD's and Andrology, Faculty of Medicine, Minia University, Al-Minya, Egypt., Elezaby RS; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt., El Hoffy NM; Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Future University in Egypt, New Cairo, Egypt.
المصدر: Drug delivery [Drug Deliv] 2022 Dec; Vol. 29 (1), pp. 1212-1231.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015->: Abingdon, Oxford : Taylor & Francis
Original Publication: Orlando, FL : Academic Press, c1993-
مواضيع طبية MeSH: Chitosan* , Melanosis*/drug therapy , Nanoparticles* , Skin Lightening Preparations*/therapeutic use, Animals ; Arbutin ; Humans ; Hydrogels ; Melanins/therapeutic use ; Mice
مستخلص: The increase in the production of melanin level inside the skin prompts a patient-inconvenient skin color disorder namely; melasma. This arouses the need to develop efficacious treatment modalities, among which are topical nano-delivery systems. This study aimed to formulate functionalized chitosan nanoparticles (CSNPs) in gel form for enhanced topical delivery of alpha-arbutin as a skin whitening agent to treat melasma. Ionic gelation method was employed to prepare α-arbutin-CSNPs utilizing a 2 4 full factorial design followed by In vitro, Ex vivo and clinical evaluation of the nano-dispersions and their gel forms. Results revealed that the obtained CSNPs were in the nanometer range with positive zeta potential, high entrapment efficiency, good stability characteristics and exhibited sustained release of α-arbutin over 24 h. Ex vivo deposition of CSNPs proved their superiority in accumulating the drug in deep skin layers with no transdermal delivery. DSC and FTIR studies revealed the successful amorphization of α-arbutin into the nanoparticulate system with no interaction between the drug and the carrier system. The comparative split-face clinical study revealed that α-arbutin loaded CSNPs hydrogels showed better therapeutic efficacy compared to the free drug hydrogel in melasma patients, as displayed by the decrease in: modified melasma area and severity index (mMASI) scores, epidermal melanin particle size surface area (MPSA) and the number of epidermal monoclonal mouse anti-melanoma antigen recognized by T cells-1 (MART-1) positive cells which proved that the aforementioned system is a promising modality for melasma treatment.
References: J Pharm (Cairo). 2016;2016:5754349. (PMID: 27885352)
Photodermatol Photoimmunol Photomed. 2012 Feb;28(1):42-6. (PMID: 22212002)
Colloids Surf B Biointerfaces. 2018 Dec 1;172:323-329. (PMID: 30176512)
J Control Release. 2004 Aug 27;98(3):427-36. (PMID: 15312998)
Int J Pharm. 2007 Oct 1;343(1-2):48-58. (PMID: 17544606)
J Dermatolog Treat. 2022 Mar 23;:1-22. (PMID: 33849384)
Biomed Res Int. 2018 Sep 25;2018:7834159. (PMID: 30356374)
Drug Dev Ind Pharm. 2019 Apr;45(4):642-650. (PMID: 30642209)
Drug Deliv Transl Res. 2019 Apr;9(2):482-496. (PMID: 29569027)
Eur J Pharm Sci. 2018 Mar 30;115:352-361. (PMID: 29407555)
Carbohydr Polym. 2016 Sep 20;149:263-73. (PMID: 27261750)
J Biomed Mater Res B Appl Biomater. 2008 Jul;86(1):197-207. (PMID: 18161791)
Dermatol Surg. 2010;36(1):76-87. (PMID: 20298254)
Int J Biol Macromol. 2018 Mar;108:753-764. (PMID: 29104049)
AAPS PharmSciTech. 2019 Jan 10;20(2):69. (PMID: 30631984)
Nanomedicine (Lond). 2015;10(13):2017-31. (PMID: 26135513)
Pharm Res. 2009 Aug;26(8):1918-30. (PMID: 19507009)
J Cosmet Dermatol. 2015 Jun;14(2):113-23. (PMID: 25847063)
Carbohydr Polym. 2018 Feb 1;181:1194-1205. (PMID: 29253949)
Sci Pharm. 2013 Apr 14;81(3):843-54. (PMID: 24106677)
Int J Pharm. 2020 Mar 15;577:119038. (PMID: 31953085)
Biol Pharm Bull. 2004 Apr;27(4):510-4. (PMID: 15056856)
Vet World. 2017 Feb;10(2):170-175. (PMID: 28344399)
Drug Deliv. 2016;23(2):601-9. (PMID: 24937378)
J Pharm Sci. 2011 Feb;100(2):612-21. (PMID: 20799365)
Nanotechnol Sci Appl. 2015 Dec 11;8:67-80. (PMID: 26715842)
Drug Deliv. 2021 Dec;28(1):973-984. (PMID: 34036860)
Dermatol Surg. 2004 May;30(5):756-60; discussion 760. (PMID: 15099320)
J Egypt Soc Parasitol. 2016 Dec;46(3):563-570. (PMID: 30230753)
Int J Biol Macromol. 2012 Dec;51(5):1127-33. (PMID: 22975304)
Dermatol Ther. 2007 Sep-Oct;20(5):343-9. (PMID: 18045359)
AAPS PharmSciTech. 2006 Jun 02;7(2):E50. (PMID: 16796367)
J Cosmet Dermatol. 2018 Jun;17(3):319-327. (PMID: 29057567)
J Investig Dermatol Symp Proc. 2008 Apr;13(1):20-4. (PMID: 18369335)
Acta Derm Venereol. 2013 May;93(3):261-7. (PMID: 23322028)
Br J Dermatol. 2006 Dec;156 Suppl 1:21-8. (PMID: 17176301)
Eur J Pharm Sci. 2019 Sep 1;137:104972. (PMID: 31252049)
J Control Release. 2000 Oct 3;69(1):169-84. (PMID: 11018555)
Pharmaceutics. 2019 Apr 22;11(4):. (PMID: 31013633)
J Cosmet Dermatol. 2012 Mar;11(1):65-71. (PMID: 22360337)
Dermatol Ther (Heidelb). 2014 Dec;4(2):165-86. (PMID: 25269451)
Int J Cosmet Sci. 2015 Oct;37(5):511-8. (PMID: 25854849)
Int J Biol Macromol. 2020 Aug 1;156:262-270. (PMID: 32289418)
Int J Pharm. 2017 Jan 10;516(1-2):170-177. (PMID: 27845211)
Expert Opin Drug Deliv. 2018 Oct;15(10):927-935. (PMID: 30169980)
Dermatol Clin. 2007 Jul;25(3):337-42, viii. (PMID: 17662899)
Biopolymers. 2008;90(5):663-70. (PMID: 18655140)
Int J Nanomedicine. 2013;8:461-75. (PMID: 23390364)
Nanomaterials (Basel). 2020 Aug 12;10(8):. (PMID: 32806538)
Adv Pharm Bull. 2014;4(2):121-30. (PMID: 24511475)
Int J Pharm. 2016 Jun 30;507(1-2):12-20. (PMID: 27130364)
Int J Mol Sci. 2016 May 26;17(6):. (PMID: 27240341)
J Nanopharm Drug Deliv. 2013 Sep;1(3):266-278. (PMID: 26989641)
Colloids Surf B Biointerfaces. 2012 Feb 1;90:169-76. (PMID: 22056083)
Int J Pharm. 2003 Mar 26;254(2):223-34. (PMID: 12623198)
Drug Dev Ind Pharm. 2005 Jan;31(1):25-34. (PMID: 15704855)
Arch Pharm Res. 2006 Dec;29(12):1187-92. (PMID: 17225471)
Int J Biol Macromol. 2017 Apr;97:616-624. (PMID: 28034824)
J Liposome Res. 2017 Mar;27(1):41-55. (PMID: 26956098)
Am J Phys Anthropol. 1975 Nov;43(3):393-408. (PMID: 1211434)
Dermatol Res Pract. 2014;2014:316219. (PMID: 25132846)
PLoS One. 2018 Jan 25;13(1):e0190976. (PMID: 29370192)
فهرسة مساهمة: Keywords: Alpha-arbutin; chitosan nanoparticles; clinical model for melasma; collagen; hyaluronic acid
المشرفين على المادة: 0 (Hydrogels)
0 (Melanins)
0 (Skin Lightening Preparations)
9012-76-4 (Chitosan)
C5INA23HXF (Arbutin)
تواريخ الأحداث: Date Created: 20220411 Date Completed: 20220412 Latest Revision: 20220429
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC9004510
DOI: 10.1080/10717544.2022.2058652
PMID: 35403519
قاعدة البيانات: MEDLINE
الوصف
تدمد:1521-0464
DOI:10.1080/10717544.2022.2058652